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Abstract  
Objective: Type 2 diabetes is strongly associated with obesity, but the mortality risk related 
to elevated body weight in people with type 2 diabetes compared with people without 
diabetes has not been established. 
Research Design and Methods: We prospectively assessed short- and long-term mortality in 
people with type 2 diabetes with a recorded diabetes duration ≤5 years identified from the 
Swedish National Diabetes Registry between 1998 and 2012 and five age- and sex matched 
controls per study participant from the general population.  
Results: Over a median follow-up of 5.5 years there were 17,546 deaths among 149,345 
patients with type 2 diabetes (mean age 59.6 years, 40% women) and 68,429 deaths among 
743,907 matched controls. Short-term all-cause mortality risk (≤5 years) displayed a U-
shaped relationship with BMI, with hazard ratios (HR) ranging from 0.81 (95% CI 0.75–
0.88) among patients with diabetes and BMI 30-<35 kg/m2 to 1.37 (95% CI 1.11–1.71) with 
BMI ≥40 kg/m2 compared with controls after multiple adjustments. Long-term, all weight 
categories showed increased mortality, with a nadir at BMI 25-<30 kg/m2 and a stepwise 
increase up to HR 2.00 (95% CI 1.58–2.54) among patients with BMI ≥40 kg/m2; more 
pronounced in patients <65 years. 
Conclusions: Our findings suggest that the apparent paradoxical findings in other 
studies in this area may have been affected by reverse causality. Long-term, overweight (BMI 
25-<30 kg/m2) patients with type 2 diabetes had low excess mortality risk compared to 
controls, whereas risk in those with BMI ≥40 kg/m2 was substantially increased.  
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Type 2 diabetes is associated with an increased risk for premature death (1-3), although this 
may be declining when compared with earlier decades (4, 5). While obesity is a major factor 
contributing to type 2 diabetes (6), reports on mortality outcomes associated with weight 
among people with type 2 diabetes are inconsistent. Some studies have reported a linear 
increase in mortality with increasing body weight (7, 8), while a J- or U-shaped relationship 
between BMI and mortality has been reported in others (9-11), or an overall J-shaped 
association between BMI and mortality among most patients, but a direct linear relationship 
among people who have never smoked (12). An obesity paradox proposes that being 
overweight, as opposed to a low BMI, might be of benefit in type 2 diabetes (13-16), 
although more recent reports indicate that any such association could be because of reverse 
causation (17) or could be confounded by smoking (17-19).  
In the current study, we investigated short-term and long-term mortality from 
cardiovascular disease (CVD) and from all causes at different BMI levels in comparison to 
age- and sex matched controls from the general population. We also aimed to investigate how 
the associations between mortality and BMI in comparison to controls are influenced by the 
time of follow up. The study used a large cohort of people with type 2 diabetes of recent 
onset (known diabetes duration ≤5 years) from the Swedish National Diabetes Register 
(NDR) with controls matched for age and sex from the general population. Body weight data 
were not available for the control group. 
 
Research Design and Methods 
Research design 
The NDR is estimated to include 90% of all Swedish patients with type 2 diabetes aged ≥18 
years. Patient data are continuously reported via electronic records from the clinic, or 
registered directly online. Thus the registry contains detailed information regarding risk 
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factors, medication and complications from diabetes. Each patient provides informed consent. 
The epidemiological definition of type 2 diabetes used was the same as in previous studies: 
treatment with oral hypoglycemic agents combined with diet or diet only, or individuals aged 
≥40 years at the time of diagnosis, treated with oral hypoglycemic agents combined with 
insulin or insulin only (4, 20). Patients included in the study had at least one registration in 
the NDR between 1 January 1998 and 31 December 2012 and were followed until 31 
December 2013. Entry point for the study was at the first time of registration. Five controls 
for each patient were randomly selected from the general population of Sweden, matched for 
age, sex, and county, generating an initial cohort of 457,473 patients and 2,287,365 controls. 
The ethics review board at the University of Gothenburg approved the study, with informed 
consent obtained from each patient in NDR. 
 
Data available for patients and controls 
To retrieve information regarding coexisting conditions and deaths, data files of patients and 
controls were linked to the Swedish Inpatient Register and Cause of Death Registries. The 
Longitudinal Database for Health Insurance and Labor Market studies provided information 
on individual income, country of birth, marital status, and highest educational level. Country 
of birth was characterized into Swedish born or foreign born while educational level was 
stratified into low (compulsory education or lower), intermediate (secondary), and high 
(university). Marital status was categorized into married/registered partner, single (never 
married or registered partner), widowed, or divorced. Patients and controls were followed 
from baseline until death or until 31 December 2013. CVD mortality was defined as any 
cardiovascular event as the underlying cause of death (Supplementary Table S1). To identify 
comorbidities such as hospitalizations for heart failure (HF), coronary heart disease (CHD), 
acute myocardial infarction (AMI), atrial fibrillation (AF), stroke, renal dialysis, and 
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transplantation, (chronic kidney disease (CKD)) from 1987 onward, codes from the 
International Classification of Diseases, 9th and 10th revisions, were used.  
 
Data available for patients only 
Hba1c was defined in millimoles per mole (mmol/mol) according to International Federation 
of Clinical Chemistry and Laboratory Medicine and converted into percent according to the 
Diabetes Control and Complications Trial (21). Microalbuminuria was defined as two 
positive tests from three samples taken within 1 year, with an albumin/creatinine ratio of 3–
30 mg/mmol (~30–300 mg/g) or U-albumin of 20–200 µg/min (20–300 mg/L), and 
macroalbuminuria as albumin/creatinine ratio >30 mg/mmol (~>300 mg/g) or U-albumin 
>200 µg/min (>300 mg/L).  
BMI was calculated using data on weight and height, collected by primary care units 
and hospital outpatient clinics. Of the patients with diabetes 112,848 (24.7%) had no data on 
weight or height at the time of their registration in the NDR. Imputation of missing BMI 
(BMI measured using kg/m2) was done using the first observed BMI. The imputation was 
restricted to values occurring within 365 days of the index date, provided that the patient did 
not suffer any serious event (registration of CHD, AMI, stroke, AF, or CKD) during that 
period. After imputation and applied exclusion criteria, 22,742 patients (13.2%) had missing 
data on BMI.  
 
Selection of study group (patients and controls)  
Controls were excluded if they had missing vital data, explained by the fact that matching 
was done by age, sex, county, and year, where some controls died before the patient’s first 
registration in the NDR. There were 4,474 people with type 2 diabetes with a BMI <20 and 
they were excluded along with their matched controls, as we considered that some of them 
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might have had other forms of, or secondary, diabetes (patients and controls after exclusion, 
n=452,999 and n=2,239,239, respectively). Patients with diabetes duration >5 years before 
registration were excluded along with their matched controls. Duration in NDR means the 
time between first being diagnosed and the day of registration in the NDR. Patients with a 
diabetes duration >5 years before registration were excluded along with their matched 
controls since the majority of patients with longer duration was included early on in the 
registry and thus were managed in another, earlier era than our selected group of patients with 
shorter duration. Patients with longer duration may also contribute to a survival bias (patients 
and controls left after exclusion, n=256,078 and n=1,268,540, respectively). Patients and 
controls were excluded along with their matched set, if there was a history of cancer or 
dementia at baseline (patients and controls left after exclusion, n=172,090 and n=857,129, 
respectively). To be able to perform Cox regression analyses for short- and long-term 
mortality risks, we additionally excluded patients and controls with zero survival time on an 
individual basis (patients and controls left after exclusion, n=172,087 and n=857,110, 
respectively). We excluded the entire matched set if the patient had missing BMI after 
imputation which generated the final cohort of patients and controls, n=149,345 and 
n=743,907, respectively. (see flow chart in Supplementary Figure S1).  
 
Statistical analysis 
Events per 1000 person-years with 95% exact (Poisson) confidence intervals were used to 
describe crude mortality. Cox regression was used for survival analysis. Patients were 
stratified into BMI categories: 20-<25, 25-<30, 30-<35, 35-<40, and ≥40 kg/m2. To fit the 
Cox regression model, we studied the association between BMI and all-cause death and CVD 
death in terms of short-term risk for death (defined as death within ≤5 years from baseline), 
including the entire cohort and where patients and controls that had died during the first time-
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period, or were followed less than five years due to end of study, were censored individually. 
In the second step, we presented the long-term mortality risk (death >5 years from baseline), 
where patients and controls surviving after 5 years were analyzed within a second time-
period, where no reassigning of patients or controls was done (Figure 1 and 2 ,Supplementary 
Figures S2–S4, Supplementary tables S15-S18, S21 and S22). To further fit the Cox 
regression model, patients with type 2 diabetes in each BMI category were compared with 
their matched controls in each BMI group (controls matched for age, sex, and county). We 
stratified the analysis for age by five equal-sized quintiles resulting in groups of(18-50], (50-
57], (57-63], (63-69] and (69- 101) years, and adjusted for years of inclusion by five equal-
sized quintiles resulting in groups of (1998-2004], (2004-2007], (2007-2009], (2009-2010] 
and (2010-2012). As the excess risk decreases with age (4), a five year duration for a young 
individual is likely different compared to a five year duration for an older individual. 
Therefore we allowed the effect of duration to be different for different ages. This was 
implemented as an interaction between duration and age. The models were adjusted for sex, 
the interaction between duration of diabetes and age, income, education, immigrant status, 
marital status, and status at baseline with respect to stroke, CHD, AMI, AF, CKD, and HF 
(Figures 1 and 2, Supplementary Figures S2-S4, Supplementary tables S15-S18, S21 and 
S22). Variables were stratified into the overall hazard ratio when the assumption of 
proportional hazards was not fulfilled, where annual income (in Swedish crowns; SEK) was 
divided into four equal quartiles of SEK 1198, SEK 1198–1732, SEK 1732–2492, and SEK 
≥2492. If a BMI group did not fulfill the non-proportional assumption for the long-term 
analysis, we censored at 12 years in a secondary analysis; however, with no significant 
change in HR, accordingly, we considered these deviations from non-proportionality as 
acceptable. We performed sub-group analyses by dividing the cohort into ≤65 years of age 
and >65 years of age (Figures 1 and 2) and by sex (Supplementary Figures S2 and S3). We 
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further examined the association between BMI and all-cause mortality and CVD mortality 
through the exclusion of patients who smoked at baseline (Supplementary Figure S4). We 
performed additional analyses among patients only, regarding the true difference in BMI 
(Supplementary tables S15-S18). To investigate any potential difference between the groups 
of patients with missing and non-missing BMI, we performed Cox regression among patients 
with missing BMI, using patients with non-missing BMI as reference (Supplementary tables 
S21 and S22) with crude mortality rates presented in Supplementary tables S19 and S20. 
The analyses were performed with R (ver. 3.2.1; R Foundation for Statistical 
Programming). All tests were two-tailed and a value of 0.05 was considered statistically 
significant. The assumption of proportional hazards was fulfilled after stratifications. 
 
Results 
Study population 
A total of 149,345 patients with type 2 diabetes and 743,907 controls were included (Table 
1). Median follow-up was 5.5 years, mean age 59.5 years, and 40% were women 
(Supplementary Table S2). Patients with type 2 diabetes were similar to controls in terms of 
marital status but had lower income and education and higher baseline prevalence of HF, 
stroke, CHD, AMI, AF, and CKD. Among patients with type 2 diabetes, age at onset was 
lowest among those with the highest BMI. Systolic blood pressure, presence of albuminuria, 
and estimated GFR increased with higher BMI, while mean LDL and mean total cholesterol 
did not differ markedly between BMI categories.  
 
Mortality 
There were 17,546 deaths among patients with type 2 diabetes, of which 7,218 (41.1%) were 
from CVD. Corresponding figures for controls were 68,429 and 27,854 (40.7%). Crude and 
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adjusted mortality rates for individuals with diabetes in relation to controls are shown along 
with the number of events in Table 2. The overall mortality rate for patients was 19.7 (19.4–
20.0) for all-cause mortality and 8.09 (7.90–8.27) for CVD mortality. The corresponding 
rates for controls were 15.2 (15.1–15.3) and 6.17 (6.10–6.25). Event rates, mortality rates, 
and person-years for Figures 1 and 2 and Supplementary Figures S2–S4 are presented in 
Supplementary Tables S3–S14.  
 
Short-term mortality at 5 years or fewer from baseline 
Figures 1 and 2 show Cox regression models for short-term (within 5 years) and long-term 
(after 5 years) all-cause and CVD mortality compared with controls by age (<65 and ≥65 
years), with all models adjusted or stratified for inclusion by year, age group, duration by age, 
income, marital status, education, immigrant status, CHD, AMI, HF, AF, and CKD. In the 
short-term (<5 years) and in patients ≥65 years of age, the association between mortality and 
BMI was U-shaped (Figure 1), but the only patients with a significantly excess risk for 
mortality were those with BMI ≥40 with HR 1.37 (95% CI 1.58–2.54) in the overall cohort 
and 1.79 (95% CI 1.33–2.40) among those aged <65 years. With respect to death occurring 
within 5 years, the total group of patients and those ≥65 years of age with a BMI 25-<30, 30-
<35, or 35-<40 had 19–30% lower short-term risk for death from any cause when compared 
with controls.  
For the overall short-term all-cause and CVD mortality, the association by BMI was 
also U-shaped, where the majority of BMI groups had a lower risk for death compared with 
controls.  Patients aged ≥65 years in the BMI range 20 up to <40 kg/m2 had 20–34% lower 
risk for death from any cause or cardiovascular causes than controls. However, patients with 
a BMI ≥40 tended to have a higher risk, irrespective of age, but the only significant increase 
in CVD mortality was found among patients aged <65 years with a BMI ≥40 (HR 1.85, 95% 
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CI 1.31–2.62) (Figure 2). The reverse linear association that was found short-term, among 
patients <65 years of age with respect to all-cause mortality (Figure 1), was tested in 
Supplementary table S17, among patients only, displayed largely the same associations short-
term.   
 
Long-term  mortality at more than 5 years from baseline 
For mortality at more than 5 years from baseline, patients with a BMI ≥30 had increased total 
and CVD mortality compared with controls. The association was J-shaped and was tested 
among patients only in Supplementary tables S15 and S16, which displayed a significant 
increase in mortality from BMI 35 (all-cause mortality) and BMI 30 (CVD mortality).  
However, among patients aged ≥65 years, a significant excess all-cause mortality was only 
seen in patients with a BMI 35-<40 (HR 1.21, 95% CI 1.01–1.46) and among the very obese 
(BMI ≥40) (HR 1.76, 95% CI 1.29–2.40). For CVD mortality among patients aged ≥65 years, 
only those with a BMI ≥40 had an increased risk (HR 2.31, 95% CI 1.59–3.37) (Figures 1 
and 2).  
Among younger people, all BMI categories displayed an increased risk for overall and 
CVD death, with a J-shaped association with a nadir at BMI 25-<30. With increasing BMI, 
there was a stepwise increase up to a HR 2.06 (95% CI 1.41–3.01) (all-cause mortality) and 
HR 2.85 (95% CI 1.88–4.43) (CVD mortality) among patients with a BMI ≥40 (Figures 1 and 
2). Women had a generally lower mortality compared to controls, than men with respect to 
both short-term and long-term mortality, with similar associations by BMI as the overall 
cohort (Supplementary Figures S2 and S3). The results among younger patients only 
displayed an increase in mortality for death from any cause and CVD causes, and with only a 
very marginal, or no increase at lower BMI levels (Supplementary tables S17 and S18). 
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In analyses restricted to non-smoking patients <65 years of age (Supplementary 
Figure S4), the long-term apparent increase in CVD mortality attenuated to the null among 
patients with a BMI 20-<25, and was not significantly different from controls with HR 1.07 
(95% CI 0.72–1.58). 
 
Missing data 
We identified an increased mortality risk among those with missing BMI (22,742/172,090), 
more pronounced in the short-term perspective.  
 
Conclusions 
In this nationwide study of patients with type 2 diabetes of recent onset, overall short-term 
mortality was slightly lower than that of the general population when grouped by a range of 
BMI between 20 and <40 kg/m2. Only patients with a BMI ≥40 showed a significantly excess 
risk. Long-term risk for patients who survived 5 years after baseline varied by age, such that 
among individuals aged ≥65 years only the very obese had an excess risk. All BMI categories 
of patients aged <65 years had higher risks compared with controls. The curve was J-shaped, 
with the lowest mortality risk among those who were moderately overweight. The 
substantially increased long-term risk in the obese does not support an alleged influence of 
reverse causality and, as such, are in opposition to a significant obesity paradox in diabetes.  
Earlier studies have shown a U-shaped or J-shaped association between BMI and all-
cause mortality among people with type 2 diabetes (9-12); however, a lower risk for mortality 
with increasing BMI has been reported among people with type 2 diabetes (13-15). Studies 
on BMI and CVD mortality among people with type 2 diabetes have reported varying results 
in terms of higher CVD mortality risk (14), lower risk (7), and U-shaped risk (22) in people 
who are overweight or obese. However, none of these studies compared the risk with 
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matched controls. In the current study, associations between BMI and mortality varied 
depending on age and duration of follow-up. A significantly higher risk for mortality among 
younger patients in the normal weight range was observed in both the short-term and long-
term. In older patients, there was only a slight increase in the risk for mortality among 
patients surviving at least 5 years from baseline but no short-term increased risk.  
Among the general population, younger people with a BMI <25 have the lowest 
mortality (23-25). Our younger (<65 years of age) cohort of patients with type 2 diabetes 
displayed a J-shaped long-term all-cause and CVD mortality curve. All BMI groups had 
long-term mortality risks higher than their matched controls, consistent with earlier studies 
(4, 10), even with good glycemic control (4). For BMI, the short-term mortality risk was 
similar or lower than that for controls over a BMI range between 25 and <40 kg/m2. Long-
term, the lowest risk for overall and CVD mortality was found among patients with a BMI 
25-<30, and a substantially increased risk among the very obese. Our analyses among 
patients only, displayed however, a near-linear BMI-mortality risk for both death from any 
cause and CVD causes. These results emphasize the importance of weight control and the 
avoidance of obesity for younger patients over the long-term, even though the true excess risk 
by diabetes for obese patients compared to non-diabetic obese persons cannot be quantified, 
since no data exits BMI for population controls. 
Among patients aged ≥65 years, all-cause and CVD mortality risks were lower or 
similar to that of matched controls, with the exception of long-term risk among patients with 
a BMI ≥35. Mortality among patients with type 2 diabetes is reported to be lower in older 
patients (3, 5, 10) compared to that of the general population, perhaps explaining the low 
short- and long-term increased mortality risks in this age group. Among patients aged ≥65, 
the very obese (BMI ≥40) had an approximately two-fold increase in long-term mortality risk 
compared with controls (all-cause and CVD).  
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In western Europe, obesity has increased, as for many other high-income countries, 
although the prevalence of obesity is lower in Sweden compared to the high-income English-
speaking countries. Since obesity is associated with higher mortality risk from any cause and 
CVD causes, in the general population (23), the increase in obesity in recent decades will 
probably contribute to an increased mortality risk and the risk for CVD among our control 
group. Even though our study population with type 2 diabetes will have had a higher 
prevalence of obesity (48.3% patients had BMI 30 or above) than the general population and 
subsequently possibly more CVD, the generally low or lower risk compared to the general 
population in all age groups, could be explained by the short diabetes duration in our selected 
cohort. Also patients with new-onset diabetes see health care providers at regular intervals, 
which could optimize their treatment for e.g. hypertension; whereas management in the 
general Swedish population is far from optimal (27).  
Among patients aged <65 with a BMI 20-<25, both short-term and long-term 
mortality were higher than that of the general population. A reason for the increased risk 
among patients with a low weight may be because of a more aggressive phenotype (11, 28), 
and perhaps even more so among the youngest patients. These patients were more often on 
insulin compared with the other groups, suggesting that this group might include a proportion 
of patients with latent autoimmune diabetes in adults or other forms of diabetes (28). 
The group with a BMI 20-<25 was large and well-medicated at baseline, although 
with a higher prevalence of smoking, insulin dependency, AF, and stroke. In many (but not 
all), lower weight may be an example of reverse causation (17, 29). Because there was no 
information about these factors in the general population, they could not be adjusted for in the 
analyses. Given the higher risk at the lower range of BMI, subclinical illness could still be an 
issue and could be more in the short-term compared with the long-term risk, which we 
identified among patients aged <65. Current guidelines advocate maintaining a healthy 
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weight as an important part of diabetes care (30) and our data supports this view, although 
not among older patients with BMI <35.  
Strengths of the study include the very large population of patients with type 2 
diabetes and the availability of a non-diabetic control population matched for age and sex. 
There may have been some patients with diabetes among the controls, as well as a proportion 
with undiagnosed diabetes, but because of the very high coverage of patients with type 2 
diabetes in the NDR, this would have been unlikely to influence our findings more than 
marginally. Our register-based study provided detailed data on cause of death, socioeconomic 
status, and risk factors for patients as well as for major comorbidities, which also made it 
possible to exclude patients and controls with cancer and dementia. Further, we had a 
uniquely high number of obese participants with excessive BMI, with more than 27,000 
patients with a BMI ≥35. We also examined mortality risk at ≤5 years and >5 years, an 
important consideration given the much higher risk for reverse causality with a shorter 
follow-up. 
This study had some limitations. There were no data on BMI or other individual risk 
factors among the general population. Thus we cannot draw any conclusions about the excess 
risk compared to controls with the same BMI. Our conclusions are strictly based on patients 
versus the average person with approximately BMI 26 kg/m2 (23), in the general population 
without diabetes, displaying the excess risk for the type 2 diabetes and BMI combined. 
Conclusions from previous studies (23, 24), indicate an increased mortality with excess 
weight among the general population but the true excess risk from type 2 diabetes in obese 
subjects cannot be estimated in the present study.. Also, 22,742 patients had missing data on 
BMI. Although causes are unknown, baseline suggests a higher frequency of comorbidities 
and albuminuria among this group of patients. The increased mortality for patients with 
missing BMI may have caused a slight bias in the short-term perspective.  Even so, we were 
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able to adjust our analyses with matched controls for a number of other factors such as 
marital status, immigration, and major diagnoses in all models comprising controls.   
In conclusion, in this large population of patients with type 2 diabetes of recent onset 
the overall short-term excess risk associated with moderately high BMI for death from any 
cause or from CVD was low, except among the very obese. The association with long-term 
mortality was J-shaped and the mortality risk increased gradually from BMI 30. Excess all-
cause mortality and CVD mortality were markedly higher among younger people, and 
patients with a BMI ≥40 had an approximately two- to three-fold excess risk, compared to the 
average non-diabetic person, irrespective of age. A BMI <25 may portend a more complex 
diabetes panorama, with increased mortality risk from non- CVD causes, potentially 
indicating reverse causality.  
Our findings suggest that the apparent paradoxical findings in other studies in this 
area may have been affected by reverse causality and that weight management remains an 
important aspect of care in a large proportion of diabetes patients.  
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Figure legends 
Figure 1 Adjusted hazard ratio (HR) for death from any cause by BMI group and time with 
age- and sex matched controls as reference 
White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis was 
based on Cox regression and adjusted for age group, year of inclusion, sex, the interaction 
between duration of diabetes and age, income, education, marital status, immigrant status, 
coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure, 
and chronic kidney disease. Variables that were non-proportional were adjusted for by 
stratification into the overall hazard ratio. Panel A, All-cause mortality, HR by BMI group 
and time. Panel B, All-cause mortality, HR by BMI group and time (age <65 years). Panel C, 
All-cause mortality, HR by BMI group and time (age ≥65 years). 
 
Figure 2 Adjusted hazard ratio (HR) for death from cardiovascular (CVD) causes by BMI 
group and time with age- and sex matched controls as reference 
White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis was 
based on Cox regression and adjusted for age group, year of inclusion, sex, the interaction 
between duration of diabetes and age, income, education, marital status, immigrant status, 
coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure, 
and chronic kidney disease. Variables that were non-proportional were adjusted for by 
stratification into the overall hazard ratio. Panel A, CVD mortality, HR by BMI group and 
time. Panel B, CVD mortality, HR by BMI group and time (age <65 years). Panel C, CVD 
mortality, HR by BMI group and time (age ≥65 years). 
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Table 1 Baseline characteristics of patients with type 2 diabetes and controls matched for age, sex, and county 
 
 
Controls 
Patients, 
overall 20 to <25 25 to <30 30 to <35 35 to <40 40 or above 
Patients with 
missing BMI 
Individuals, n 743907 149345 20297 56943 44266 18766 9073 22742 
Age and sex 
Women  297304 (40.0) 59669 (40.0) 8783 (43.3) 19467 (34.2) 17386 (39.3) 9021 (48.1) 5012 (55.2) 9755 (42.9) 
Age (years) 59.5 (11.7) 59.6 (11.7) 62.4 (12.7) 61.2 (11.2) 59.0 (11.1) 56.3 (11.4) 52.8 (11.9) 60.8 (13.5) 
Socioeconomic status 
Marital status, n (%) 
    Divorced 122495 (16.5) 25936 (17.4) 3365 (16.6) 9720 (17.1) 7904 (17.9) 3378 (18.0) 1569 (17.3) 4120 (18.1) 
    Married 423314 (56.9) 81116 (54.3) 11233 (55.3) 32937 (57.8) 23876 (53.9) 9207 (49.1) 3863 (42.6) 11468 (50.4) 
    Single 142400 (19.1) 29923 (20.0) 3481 (17.2) 9363 (16.4) 9025 (20.4) 4899 (26.1) 3155 (34.8) 4661 (20.5) 
    Widowed 55658 (7.5) 12370 (8.3) 2218 (10.9) 4923 (8.6) 3461 (7.8) 1282 (6.8) 486 (5.4) 2493 (11.0) 
Education, n (%) 
    10 to 12 years 315184 (42.9) 66414 (45.1) 8154 (40.8) 24566 (43.8) 20018 (45.9) 9049 (49.0) 4627 (51.8) 9525 (43.1) 
    9 years or fewer  219552 (29.9) 54721 (37.2) 7573 (37.9) 21192 (37.7) 16434 (37.7) 6563 (35.5) 2959 (33.2) 8543 (38.7) 
    College or university 200203 (27.2) 26015 (17.7) 4269 (21.3) 10392 (18.5) 7149 (16.4) 2865 (15.5) 1340 (15.0) 4031 (18.2) 
Income (hundreds, SEK
*
), median 
[interquartile range] 
1775.0 [1214.0, 
2543.0] 
1543.0 [1133.0, 
2232.0] 
1455.0 [1083.0, 
2143.0] 
1576.0 [1144.0, 
2277.0] 
1564.0 [1148.0, 
2261.0] 
1538.0 [1138.0, 
2193.0] 
1466.0 [1106.0, 
2107.0] 
1437.0 [1075.0, 
2119.0] 
Swedish born, n (%) 647467 (87.0) 120880 (80.9) 16778 (82.7) 46175 (81.1) 35557 (80.3) 15092 (80.4) 7278 (80.2) 17928 (78.8) 
Comorbidities 
Atrial fibrillation 20755 (2.8) 7199 (4.8) 1100 (5.4) 2689 (4.7) 2068 (4.7) 882 (4.7) 460 (5.1) 1535 (6.7) 
Myocardial infarction 21229 (2.9) 10184 (6.8) 1277 (6.3) 4288 (7.5) 3156 (7.1) 1115 (5.9) 348 (3.8) 1830 (8.0) 
Coronary heart disease 41799 (5.6) 18673 (12.5) 2318 (11.4) 7787 (13.7) 5776 (13.0) 2097 (11.2) 695 (7.7) 3310 (14.6) 
Stroke 17687 (2.4) 5824 (3.9) 976 (4.8) 2423 (4.3) 1617 (3.7) 567 (3.0) 241 (2.7) 1456 (6.4) 
Heart failure 10909 (1.5) 5570 (3.7) 724 (3.6) 1958 (3.4) 1662 (3.8) 808 (4.3) 418 (4.6) 1329 (5.8) 
Renal dialysis or transplantation 778 (0.1) 206 (0.1) 60 (0.3) 90 (0.2) 40 (0.1) 9 (0.0) 7 (0.1) 56 (0.2) 
Variables from NDR†  
Diabetes duration (years) NA 1.5 (1.6) 1.6 (1.6) 1.5 (1.6) 1.4 (1.6) 1.4 (1.6) 1.3 (1.5) 1.6 (1.6) 
Onset age of diabetes (years) NA 58.1 (11.7) 60.8 (12.7) 59.6 (11.2) 57.5 (11.0) 55.0 (11.4) 51.5 (11.8) 59.2 (13.4) 
HbA1c (%)/(mmol/mol) NA 
7.0 (1.4)/53.3 
(15.5) 
6.9 (1.5)/52.4 
(16.6) 
6.9 (1.4)/52.4 
(15.1) 
7.1 (1.4)/53.6 
(15.2) 
7.2 (1.4)/54.7 
(15.5) 
7.3 (1.5)/56.0 
(16.3) 53.7 (16.1) 
Total cholesterol (mmol/L) NA 5.2 (1.1) 5.1 (1.1) 5.2 (1.1) 5.2 (1.1) 5.2 (1.1) 5.1 (1.1) 5.1 (1.2) 
Page 22 of 50
CONFIDENTIAL-For Peer Review Only
Diabetes Care
23 
LDL cholesterol (mmol/L) NA 3.0 (1.0) 3.0 (1.0) 3.1 (1.0) 3.0 (1.0) 3.0 (0.9) 3.0 (0.9) 3.0 (1.0) 
Smokers, n (%) NA 25429 (18.1) 3979 (20.8) 9419 (17.6) 7311 (17.6) 3145 (17.9) 1575 (18.6) 2816 (18.0) 
Body mass index (kg/m
2
) NA 30.6 (5.5) 23.3 (1.3) 27.6 (1.4) 32.2 (1.4) 37.1 (1.4) 44.1 (4.2) NA 
Systolic blood pressure (mmHg) NA 137.5 (17.5) 135.7 (18.7) 137.3 (17.5) 138.1 (17.2) 138.1 (16.9) 138.1 (16.9) 138.5 (18.3) 
Diastolic blood pressure (mmHg) NA 80.0 (9.8) 77.1 (9.4) 79.4 (9.5) 81.0 (9.8) 81.8 (10.0) 82.6 (10.3) 79.9 (10.0) 
Albuminuria, n (%) 
    Microalbuminuria NA 13201 (11.9) 1502 (9.8) 4713 (11.1) 4136 (12.6) 1947 (14.2) 903 (13.9) 1436 (12.3) 
    Macroalbuminuria NA 5709 (5.1) 665 (4.3) 2017 (4.7) 1755 (5.4) 843 (6.1) 429 (6.6) 752 (6.4) 
eGFR
‡
 (mL/min/1.73 m
2
) NA 86.2 (23.0) 85.2 (24.0) 84.7 (22.0) 86.3 (22.7) 88.8 (23.5) 92.3 (25.1) 85.6 (26.0) 
Anti-hypertensives, n (%) NA 82810 (59.0) 9077 (47.7) 30566 (57.0) 26328 (63.4) 11462 (65.0) 5377 (63.4) 11610 (57.6) 
Statins, n (%) NA 53836 (38.3) 6278 (33.0) 21172 (39.4) 17044 (40.9) 6682 (38.0) 2660 (31.5) 7538 (37.4) 
Diabetes treatment, NDR, n (%) 
    No pharmacological treatment NA 65068 (43.6) 9185 (45.3) 25770 (45.3) 19201 (43.4) 7497 (39.9) 3415 (37.6) 9855 (43.3) 
    Oral agents NA 65934 (44.1) 7053 (34.7) 24100 (42.3) 20497 (46.3) 9498 (50.6) 4786 (52.7) 9349 (41.1) 
    Insulin NA 10116 (6.8) 3156 (15.5) 4129 (7.3) 1957 (4.4) 629 (3.4) 245 (2.7) 1933 (8.5) 
    Insulin and oral agents NA 8227 (5.5) 903 (4.4) 2944 (5.2) 2611 (5.9) 1142 (6.1) 627 (6.9) 1605 (7.1) 
 
*SEK, Swedish kronor, †NDR, Swedish National Diabetes Registry, ‡eGFR, estimated glomerular filtration rate. Data for continuous variables are mean (standard 
deviation) with the exception of “Income”, which is median [interquartile range]. Data for categorical variables are frequencies (percent). Income is given in 
hundred SEK. 
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Table 2 Crude mortality rates per 1 000 person years for all-cause mortality and 
cardiovascular disease (CVD) mortality among patients with type 2 diabetes and controls in 
the entire cohort 
All-cause mortality 
Category Events Person-years Mortality rate 
Patients 17546 892672 19.7 (19.4–20.0) 
Control 68429 4511754 15.2 (15.1–15.3) 
Patients by BMI 
    20 to <25 3499 127131 27.5 (26.6–28.5) 
    25 to <30 7171 349341 20.5 (20.1–21.0) 
    30 to <35 4479 261060 17.2 (16.7–17.7) 
    35 to <40 1665 106075 15.7 (15.0–16.5) 
    40 or above 732 49065 14.9 (13.9–16.0) 
CVD mortality 
Category Events Person-years Mortality rate  
Patients 7218 892672 8.09 (7.90–8.27) 
Control 27854 4511754 6.17 (6.10–6.25) 
Patients by BMI 
    20 to <25 1423 127131 11.2 (10.6–11.8) 
    25 to <30 2966 349341 8.49 (8.19–8.80) 
    30 to <35 1832 261060 7.02 (6.70–7.35) 
    35 to <40 700 106075 6.60 (6.12–7.11) 
    40 or above 297 49065 6.05 (5.38–6.78) 
 
Events and person-years are numbers. Mortality rates are mean (95% CI). 
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Figure 1 Adjusted hazard ratio (HR) for death from any cause by BMI group and time with age- and sex 
matched controls as reference  
White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis was based on Cox 
regression and adjusted for age group, year of inclusion, sex, the interaction between duration of diabetes 
and age, income, education, marital status, immigrant status, coronary heart disease, acute myocardial 
infarction, stroke, atrial fibrillation, heart failure, and chronic kidney disease. Variables that were non-
proportional were adjusted for by stratification into the overall hazard ratio. Panel A, All-cause mortality, HR 
by BMI group and time. Panel B, All-cause mortality, HR by BMI group and time (age <65 years). Panel C, 
All-cause mortality, HR by BMI group and time (age ≥65 years).  
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Figure 2 Adjusted hazard ratio (HR) for death from cardiovascular (CVD) causes by BMI group and time with 
age- and sex matched controls as reference  
White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis was based on Cox 
regression and adjusted for age group, year of inclusion, sex, the interaction between duration of diabetes 
and age, income, education, marital status, immigrant status, coronary heart disease, acute myocardial 
infarction, stroke, atrial fibrillation, heart failure, and chronic kidney disease. Variables that were non-
proportional were adjusted for by stratification into the overall hazard ratio. Panel A, CVD mortality, HR by 
BMI group and time. Panel B, CVD mortality, HR by BMI group and time (age <65 years). Panel C, CVD 
mortality, HR by BMI group and time (age ≥65 years).  
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 SUPPLEMENTARY DATA 
Original cohort 
Patients with type 2 diabetes, n = 457 473 
Controls, n = 2 287 365   
Cohort left after exclusion of inconsistent vital 
data 
Patients with type 2 diabetes, n = 457 473 
Controls, n = 2 261 150  
Cohort left with imputed BMI at baseline 
Patients with type 2 diabetes, n = 149 345 
Controls, n = 743 907  
Cohort left with BMI ≥20 
Patients with type 2 diabetes, n = 452 999 
Controls, n = 2 239 239 
Cohort left with diabetes duration  ≤5 years 
Patients with type 2 diabetes, n = 256 078 
Controls, n = 1 268 540 
Cohort left without patients or controls with a 
history of cancer or dementia 
Patients with type 2 diabetes, n = 172 090 
Controls, n = 857 129 
- Patients excluded, n = 22 742 
- Controls excluded, n = 113 203 
Controls excluded, n = 26 215 
Patients excluded, n = 3 
Controls excluded, n = 19 
Patients excluded, n = 83 988 
Controls excluded, n = 411 411 
Cohort left with survivonly al time zero 
Patients with type 2 diabetes, n=172 087 
Controls, n=857 110 
Patients excluded, n = 4 474 
Controls excluded, n = 21 911 
- Patients excluded, n = 196 921 
- Controls exluded, n = 970 699 
The complete matched set (1 patient & 5, controls) 
was excluded if a patient had missing BMI or 
could not be imputed. 
The complete matched set, (1 patient & 5 controls) 
was excluded if a patient or control had a history 
of cancer or dementia.  
Patients and controls were excluded individually 
if either of them had survival time zero. 
Exclude controls with inconsistent vital data 
(negative survival). 
Supplementary Figure S1-Flow 
chart 
The complete matched set (1 patient & 5 controls) 
was excluded if a patient had BMI <20. . 
The complete matched set, i.e 1 patient & 5 
controls, was excluded if a patient diabetes 
duration >5 years. 
Legends: Overview of the study 
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Supplementary table S1-Descriptions of diagnoses used from the International Classification of 
Diseases system 
Diagnosis ICD-9 ICD-10 
Coronary heart disease 410-414 I20-I25 
Acute myocardial infarction 410 I21 
Stroke 
431, 432X, 433, 434, 436, 
437X I61, I62.9, I63, I64, I67.9 
Heart failure 428 I50 
Atrial fibrillation 427D I48 
Renal dialysis or 
transplantation V42A, V45B, V56A, V56W Z94.0, Z49, Z99.2 
Cancer 140-208 C00-C97 
Dementia - G30, F00-F03, F05 
Cardiovascular mortality - 
I00-I99 as underlying cause of 
death 
Legends: Diagnosis used from the inpatient registry according to the International Classification of 
Diseases (ICD) system, 9
th
 revision and 10
th
 revision. 
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Supplementary table S2-
descriptives 
Median follow-up years 5.46. 
Age (Mean) 59.52. 
Age (SD) 11.68. 
Deaths from any cause 
(n) 
85 975 
Cardiovascular deaths 
(n) 
35 072 
Heart failure (n) 37 564 
Cardiac heart disease 
(n) 
78 870 
Stroke (n) 33 608 
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Supplementary table S3 - Short term (≤5 years) and long term (>5 years) overall crude all-
cause mortality rates for patients with type 2 diabetes by BMI and controls matched to BMI 
group by age, sex and county 
Mortality ≤ 5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 1892 84513 22.39 (21.39-23.42) 
Controls 7618 422921 18.01 (17.61-18.42) 
25 to <30 3677 237201 15.50 (15.00-16.01) 
Controls 16577 1181646 14.03 (13.82-14.24) 
30 to <35 2188 181259 12.07 (11.57-12.59) 
Controls 9572 904221 10.59 (10.37-10.80) 
35 to <40 811 75502 10.74 (10.01-11.51) 
Controls 2971 378046 7.86 ( 7.58- 8.15) 
40 or above 389 35892 10.84 ( 9.79-11.97) 
Controls 903 181197 4.98 ( 4.66- 5.32) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 1607 42618 37.71 (35.89-39.60) 
Controls 6180 222906 27.72 (27.04-28.42) 
25 to <30 3494 112140 31.16 (30.13-32.21) 
Controls 13653 575282 23.73 (23.34-24.13) 
30 to <35 2291 79801 28.71 (27.55-29.91) 
Controls 7835 413796 18.93 (18.52-19.36) 
35 to <40 854 30573 27.93 (26.09-29.87) 
Controls 2350 160538 14.64 (14.05-15.24) 
40 or above 343 13174 26.04 (23.35-28.94) 
Controls 770 71202 10.81 (10.06-11.61) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S4 - Short term (≤5 years) and long term (>5 years) crude mortality rates 
for patients with type 2 diabetes by BMI aged <65 years of age and controls matched to BMI 
group by age, sex and county 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 413 48029  8.60 ( 7.79- 9.47) 
Controls 1051 242029  4.34 ( 4.08- 4.61) 
25 to <30 982 148884  6.60 ( 6.19- 7.02) 
Controls 3464 746187  4.64 ( 4.49- 4.80) 
30 to <35 827 125407  6.59 ( 6.15- 7.06) 
Controls 2704 628724  4.30 ( 4.14- 4.47) 
35 to <40 350 57422  6.10 ( 5.47- 6.77) 
Controls 1082 287824  3.76 ( 3.54- 3.99) 
40 or above 227 29838  7.61 ( 6.65- 8.66) 
Controls 408 150423  2.71 ( 2.46- 2.99) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 355 26836 13.23 (11.89-14.68) 
Controls 997 138756  7.19 ( 6.75- 7.65) 
25 to <30 938 73569 12.75 (11.95-13.59) 
Controls 3064 376534  8.14 ( 7.85- 8.43) 
30 to <35 814 56670 14.36 (13.39-15.39) 
Controls 2211 293934  7.52 ( 7.21- 7.84) 
35 to <40 395 23709 16.66 (15.06-18.39) 
Controls 823 123401  6.67 ( 6.22- 7.14) 
40 or above 174 11036 15.77 (13.51-18.29) 
Controls 291 58279  4.99 ( 4.44- 5.60) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S5 - Short term (≤5 years) and long term (>5 years) crude all-cause 
mortality rates for patients with type 2 diabetes by BMI aged ≥65 years of age and controls 
matched to BMI group by age, sex and county 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 1479 36484 40.54 (38.50-42.66) 
Controls 6567 180892 36.30 (35.43-37.19) 
25 to <30 2695 88317 30.52 (29.37-31.69) 
Controls 13113 435458 30.11 (29.60-30.63) 
30 to <35 1361 55852 24.37 (23.09-25.70) 
Controls 6868 275497 24.93 (24.34-25.53) 
35 to <40 461 18080 25.50 (23.22-27.94) 
Controls 1889 90222 20.94 (20.00-21.90) 
40 or above 162 6053 26.76 (22.80-31.22) 
Controls 495 30773 16.09 (14.70-17.57) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 1252 15782 79.33 (75.00-83.85) 
Controls 5183 84150 61.59 (59.93-63.29) 
25 to <30 2556 38571 66.27 (63.72-68.89) 
Controls 10589 198748 53.28 (52.27-54.30) 
30 to <35 1477 23131 63.85 (60.64-67.20) 
Controls 5624 119862 46.92 (45.70-48.16) 
35 to <40 459 6864 66.87 (60.89-73.28) 
Controls 1527 37138 41.12 (39.08-43.23) 
40 or above 169 2137 79.08 (67.61-91.95) 
Controls 479 12924 37.06 (33.82-40.54) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S6 - Short term (≤5 years) and long term (>5 years) crude all-cause 
mortality rates for patients with type 2 diabetes by BMI and controls matched to BMI group by 
age, sex and county among men only 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 1113 47760 23.30 (21.95-24.71) 
Controls 4259 239632 17.77 (17.24-18.32) 
25 to <30 2436 156269 15.59 (14.98-16.22) 
Controls 10649 779290 13.67 (13.41-13.93) 
30 to <35 1394 109762 12.70 (12.04-13.38) 
Controls 5695 548333 10.39 (10.12-10.66) 
35 to <40 474 38863 12.20 (11.12-13.35) 
Controls 1572 194957  8.06 ( 7.67- 8.47) 
40 or above 197 15927 12.37 (10.70-14.22) 
Controls 411 80525  5.10 ( 4.62- 5.62) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 854 23829 35.84 (33.48-38.33) 
Controls 3330 124843 26.67 (25.78-27.60) 
25 to <30 2232 73702 30.28 (29.04-31.57) 
Controls 8539 379939 22.47 (22.00-22.96) 
30 to <35 1362 47189 28.86 (27.35-30.44) 
Controls 4477 247220 18.11 (17.58-18.65) 
35 to <40 440 15068 29.20 (26.54-32.06) 
Controls 1136 80218 14.16 (13.35-15.01) 
40 or above 166 5594 29.67 (25.33-34.55) 
Controls 322 30837 10.44 ( 9.33-11.65) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S7 - Short term (≤5 years) and long term (>5 years) crude all-cause 
mortality rates for patients with type 2 diabetes by BMI and controls matched to BMI group by 
age, sex and county among women only 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 779 36753 21.20 (19.73-22.74) 
Controls 3359 183288 18.33 (17.71-18.96) 
25 to <30 1241 80932 15.33 (14.49-16.21) 
Controls 5928 402356 14.73 (14.36-15.11) 
30 to <35 794 71497 11.11 (10.35-11.91) 
Controls 3877 355888 10.89 (10.55-11.24) 
35 to <40 337 36639  9.20 ( 8.24-10.23) 
Controls 1399 183089  7.64 ( 7.25- 8.05) 
40 or above 192 19965  9.62 ( 8.30-11.08) 
Controls 492 100672  4.89 ( 4.46- 5.34) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 753 18789 40.08 (37.26-43.04) 
Controls 2850 98062 29.06 (28.01-30.15) 
25 to <30 1262 38438 32.83 (31.05-34.69) 
Controls 5114 195343 26.18 (25.47-26.91) 
30 to <35 929 32612 28.49 (26.68-30.38) 
Controls 3358 166577 20.16 (19.48-20.85) 
35 to <40 414 15504 26.70 (24.19-29.40) 
Controls 1214 80321 15.11 (14.28-15.99) 
40 or above 177 7580 23.35 (20.04-27.06) 
Controls 448 40365 11.10 (10.09-12.18) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S8 - Short term (≤5 years) and long term (>5 years) crude all-cause 
mortality rates for non-smoking patients with type 2 diabetes by BMI aged <65 years of age 
and controls matched to BMI group by age, sex and county 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortailty rate  
20 to <25 201 32927  6.10 ( 5.29- 7.01) 
Controls 715 165071  4.33 ( 4.02- 4.66) 
25 to <30 560 109810  5.10 ( 4.69- 5.54) 
Controls 2578 548344  4.70 ( 4.52- 4.89) 
30 to <35 488 92712  5.26 ( 4.81- 5.75) 
Controls 2016 463523  4.35 ( 4.16- 4.54) 
35 to <40 211 42458  4.97 ( 4.32- 5.69) 
Controls 804 212261  3.79 ( 3.53- 4.06) 
40 or above 140 22082  6.34 ( 5.33- 7.48) 
Controls 326 110941  2.94 ( 2.63- 3.28) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortailty rate  
20 to <25 170 18902  8.99 ( 7.69-10.45) 
Controls 690 95367 7.24 ( 6.71- 7.80) 
25 to <30 591 55461 10.66 ( 9.81-11.55) 
Controls 2331 279758  8.33 ( 8.00- 8.68) 
30 to <35 515 42496 12.12 (11.09-13.21) 
Controls 1675 217109  7.72 ( 7.35- 8.09) 
35 to <40 263 17972 14.63 (12.92-16.51) 
Controls 624 92349  6.76 ( 6.24- 7.31) 
40 or above 117 8331 14.04 (11.61-16.83) 
Controls 218 43487  5.01 ( 4.37- 5.72) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S9 - Short term (≤5 years) and long term (>5 years) overall crude CVD 
mortality rates for patients with type 2 diabetes by BMI and controls matched to BMI group by 
age, sex and county 
Mortality ≤5 
Patients by BMI and matched controls Events Person years Mortality rate 
20 to <25 776 84513  9.18 ( 8.55- 9.85) 
Controls 3393 422921  8.02 ( 7.76- 8.30) 
25 to <30 1522 237201  6.42 ( 6.10- 6.75) 
Controls 6945 1181646  5.88 ( 5.74- 6.02) 
30 to <35 858 181259  4.73 ( 4.42- 5.06) 
Controls 3865 904221  4.27 ( 4.14- 4.41) 
35 to <40 330 75502  4.37 ( 3.91- 4.87) 
Controls 1062 378046  2.81 ( 2.64- 2.98) 
40 or above 152 35892  4.23 ( 3.59- 4.96) 
Controls 314 181197  1.73 ( 1.55- 1.94) 
Mortality >5 
Patients by BMI and matched controls Events Person years Mortality rate 
20 to <25 647 42618 15.18 (14.03-16.40) 
Controls 2603 222906 11.68 (11.23-12.13) 
25 to <30 1444 112140 12.88 (12.22-13.56) 
Controls 5571 575282  9.68 ( 9.43- 9.94) 
30 to <35 974 79801 12.21 (11.45-13.00) 
Controls 2986 413796  7.22 ( 6.96- 7.48) 
35 to <40 370 30573 12.10 (10.90-13.40) 
Controls 865 160538  5.39 ( 5.03- 5.76) 
40 or above 145 13174 11.01 ( 9.29-12.95) 
Controls 250 71202  3.51 ( 3.09- 3.97) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S10 - Short term (≤5 years) and long term (>5 years) crude CVD mortality 
rates for patients with type 2 diabetes by BMI aged <65 years of age and controls matched to 
BMI group by age, sex and county 
Mortality ≤5 years    
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 103 48029 2.14 (1.75-2.60) 
Controls 319 242029 1.32 (1.18-1.47) 
25 to <30 309 148884 2.08 (1.85-2.32) 
Controls 1079 746187 1.45 (1.36-1.53) 
30 to <35 266 125407 2.12 (1.87-2.39) 
Controls 869 628724 1.38 (1.29-1.48) 
35 to <40 131 57422 2.28 (1.91-2.71) 
Controls 318 287824 1.10 (0.99-1.23) 
40 or above 82 29838 2.75 (2.19-3.41) 
Controls 119 150423 0.79 (0.66-0.95) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate 
20 to <25 100 26836 3.73 (3.03-4.53) 
Controls 286 138756 2.06 (1.83-2.31) 
25 to <30 323 73569 4.39 (3.92-4.90) 
Controls 892 376534 2.37 (2.22-2.53) 
30 to <35 281 56670 4.96 (4.40-5.57) 
Controls 634 293934 2.16 (1.99-2.33) 
35 to <40 151 23709 6.37 (5.39-7.47) 
Controls 234 123401 1.90 (1.66-2.16) 
40 or above 73 11036 6.61 (5.18-8.32) 
Controls 68 58279 1.17 (0.91-1.48) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S11 - Short term (≤5 years) and long term (>5 years) crude CVD mortality 
rates for patients with type 2 diabetes by BMI aged ≥65 years of age and controls matched to BMI 
group by age, sex and county 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 673 36484 18.45 (17.08-19.89) 
Controls 3074 180892 16.99 (16.40-17.61) 
25 to <30 1213 88317 13.73 (12.97-14.53) 
Controls 5866 435458 13.47 (13.13-13.82) 
30 to <35 592 55852 10.60 ( 9.76-11.49) 
Controls 2996 275497 10.87 (10.49-11.27) 
35 to <40 199 18080 11.01 ( 9.53-12.65) 
Controls 744 90222  8.25 ( 7.66- 8.86) 
40 or above 70 6053 11.56 ( 9.02-14.61) 
Controls 195 30773  6.34 ( 5.48- 7.29) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 547 15782 34.66 (31.82-37.69) 
Controls 2317 84150 27.53 (26.42-28.68) 
25 to <30 1121 38571 29.06 (27.39-30.82) 
Controls 4679 198748 23.54 (22.87-24.23) 
30 to <35 693 23131 29.96 (27.77-32.28) 
Controls 2352 119862 19.62 (18.84-20.43) 
35 to <40 219 6864 31.91 (27.82-36.42) 
Controls 631 37138 16.99 (15.69-18.37) 
40 or above 72 2137 33.69 (26.36-42.43) 
Controls 182 12924 14.08 (12.11-16.28) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean (CI 
95%) 
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Supplementary table S12 - Short term (≤5 years) and long term (>5 years) crude CVD mortality 
rates for patients with type 2 diabetes by BMI and controls matched to BMI group by age, sex 
and county among men only 
Mortality ≤5 years    
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 460 47760  9.63 ( 8.77-10.55) 
Controls 1896 239632  7.91 ( 7.56- 8.28) 
25 to <30 1014 156269  6.49 ( 6.10- 6.90) 
Controls 4414 779290  5.66 ( 5.50- 5.83) 
30 to <35 557 109762  5.07 ( 4.66- 5.51) 
Controls 2326 548333  4.24 ( 4.07- 4.42) 
35 to <40 200 38863  5.15 ( 4.46- 5.91) 
Controls 559 194957  2.87 ( 2.63- 3.12) 
40 or above 85 15927  5.34 ( 4.26- 6.60) 
Controls 164 80525  2.04 ( 1.74- 2.37) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 340 23829 14.27 (12.79-15.87) 
Controls 1369 124843 10.97 (10.39-11.56) 
25 to <30 909 73702 12.33 (11.54-13.16) 
Controls 3405 379939  8.96 ( 8.66- 9.27) 
30 to <35 575 47189 12.19 (11.21-13.22) 
Controls 1678 247220  6.79 ( 6.47- 7.12) 
35 to <40 196 15068 13.01 (11.25-14.96) 
Controls 412 80218  5.14 ( 4.65- 5.66) 
40 or above 74 5594 13.23 (10.39-16.61) 
Controls 102 30837  3.31 ( 2.70- 4.02) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S13 - Short term (≤5 years) and long term (>5 years) crude CVD mortality 
rates for patients with type 2 diabetes by BMI and controls matched to BMI group by age, sex 
and county among women only 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 316 36753  8.60 ( 7.68- 9.60) 
Controls 1497 183288  8.17 ( 7.76- 8.59) 
25 to <30 508 80932  6.28 ( 5.74- 6.85) 
Controls 2531 402356  6.29 ( 6.05- 6.54) 
30 to <35 301 71497  4.21 ( 3.75- 4.71) 
Controls 1539 355888  4.32 ( 4.11- 4.55) 
35 to <40 130 36639  3.55 ( 2.96- 4.21) 
Controls 503 183089  2.75 ( 2.51- 3.00) 
40 or above 67 19965  3.36 ( 2.60- 4.26) 
Controls 150 100672  1.49 ( 1.26- 1.75) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortality rate  
20 to <25 307 18789 16.34 (14.56-18.27) 
Controls 1234 98062 12.58 (11.89-13.31) 
25 to <30 535 38438 13.92 (12.76-15.15) 
Controls 2166 195343 11.09 (10.63-11.57) 
30 to <35 399 32612 12.23 (11.06-13.50) 
Controls 1308 166577  7.85 ( 7.43- 8.29) 
35 to <40 174 15504 11.22 ( 9.62-13.02) 
Controls 453 80321  5.64 ( 5.13- 6.18) 
40 or above 71 7580  9.37 ( 7.32-11.81) 
Controls 148 40365  3.67 ( 3.10- 4.31) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S14 - Short term (≤5 years) and long term (>5 years) crude CVD mortality 
rates for non-smoking patients with type 2 diabetes by BMI aged <65 years of age and controls 
matched to BMI group by age, sex and county 
Mortality ≤5 years 
Patients by BMI and matched controls Events Person years Mortailty rate  
20 to <25 54 32927 1.64 (1.23-2.14) 
Controls 210 165071 1.27 (1.11-1.46) 
25 to <30 159 109810 1.45 (1.23-1.69) 
Controls 804 548344 1.47 (1.37-1.57) 
30 to <35 151 92712 1.63 (1.38-1.91) 
Controls 652 463523 1.41 (1.30-1.52) 
35 to <40 74 42458 1.74 (1.37-2.19) 
Controls 229 212261 1.08 (0.94-1.23) 
40 or above 53 22082 2.40 (1.80-3.14) 
Controls 98 110941 0.88 (0.72-1.08) 
Mortality >5 years 
Patients by BMI and matched controls Events Person years Mortailty rate  
20 to <25 50 18902 2.65 (1.96-3.49) 
Controls 212 95367 2.22 (1.93-2.54) 
25 to <30 205 55461 3.70 (3.21-4.24) 
Controls 671 279758 2.40 (2.22-2.59) 
30 to <35 170 42496 4.00 (3.42-4.65) 
Controls 476 217109 2.19 (2.00-2.40) 
35 to <40 100 17972 5.56 (4.53-6.77) 
Controls 174 92349 1.88 (1.61-2.19) 
40 or above 49 8331 5.88 (4.35-7.78) 
Controls 50 43487 1.15 (0.85-1.52) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S15 - Adjusted hazard ratio (HR) for death from any cause by BMI group 
and time, among patients only. Patients with BMI 25 to <30 used as reference. 
Mortality ≤5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.31 1.21 1.41 
25 to <30 (Ref) 1 1 1 
30 to <35 0.91 1.84 0.98 
35 to <40 0.93 0.83 1.03 
40 and above 1.14 0.99 1.33 
Mortality >5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.17 1.09 1.27 
25 to <30 (Ref) 1 1 1 
30 to <35 1.04 0.97 1.11 
35 to <40 1.13 1.02 1.25 
40 and above 1.34 1.15 1.55 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
 
Supplementary table S16 - Adjusted hazard ratio (HR) for death from CVD causes by BMI 
group and time, among patients only. Patients with BMI 25 to <30 used as reference. 
Mortality ≤5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.25 1.14 1.36 
25 to <30 (Ref) 1 1 1 
30 to <35 0.87 0.80 0.94 
35 to <40 0.95 0.84 1.08 
40 and above 1.17 0.98 1.39 
Mortality >5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.13 1.03 1.24 
25 to <30 (Ref) 1 1 1 
30 to <35 1.10 1.01 1.19 
35 to <40 1.36 1.21 1.53 
40 and above 1.59 1.33  1.89 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
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Supplementary table S17 - Adjusted hazard ratio (HR) for death from any cause by BMI group 
and time, among patients only aged <65 years. Patients with BMI 25 to <30 used as reference. 
Mortality ≤5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.41 1.26 1.59 
25 to <30 (Ref) 1 1 1 
30 to <35 1.02 0.93 1.12 
35 to <40 1.01 0.89 1.14 
40 and above 1.37 1.18 1.59 
Mortality >5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.13 1.00 1.28 
25 to <30 (Ref) 1 1 1 
30 to <35 1.15 1.04 1.26 
35 to <40 1.41 1.26 1.59 
40 and above 1.49 1.26 1.76 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
 
Supplementary table S18 - Adjusted hazard ratio (HR) for death from CVD causes by BMI 
group and time, among patients only aged <65 years. Patients with BMI 25 to <30 used as 
reference. 
Mortality ≤5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 1.14 0.91 1.43 
25 to <30 (Ref) 1 1 1 
30 to <35 1.03 0.87 1.21 
35 to <40 1.19 0.97 1.47 
40 and above 1.58 1.23 2.03 
Mortality >5 years 
BMI group HR estimate Lower CI 95% Upper CI 95% 
20 to <25 0.98 0.78 1.22 
25 to <30 (Ref) 1 1 1 
30 to <35 1.14 0.97 1.34 
35 to <40 1.55 1.27 1.87 
40 and above 1.86 1.44 2.41 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
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Supplementary table S19 - Crude mortality rates for all-cause mortality among patients with 
missing/non-missing BMI 
Group 
Missing/non-missing 
BMI among patients 
Mortality by 
time period Events 
Person 
years 
Mortality rate/1000 
person years 
Overall Missing BMI ≤5 years 2210 91302 24.21 (23.21-25.24) 
Non-missing BMI ≤5 years 8957 614367 14.58 (14.28-14.88) 
Missing BMI >5 years 1632 41755 39.09 (37.21-41.03) 
Non-missing BMI >5 years 8589 278305 30.86 (30.21-31.52) 
<65 Missing BMI ≤5 years 539 56618  9.52 ( 8.73-10.36) 
Non-missing BMI ≤5 years 2799 409580  6.83 ( 6.58- 7.09) 
Missing BMI >5 years 466 27609 16.88 (15.38-18.48) 
Non-missing BMI >5 years 2676 191821 13.95 (13.43-14.49) 
>65 Missing BMI ≤5 years 1671 34684 48.18 (45.90-50.54) 
Non-missing BMI ≤5 years 6158 204787 30.07 (29.32-30.83) 
Missing BMI >5 years 1166 14146 82.43 (77.76-87.30) 
Non-missing BMI >5 years 5913 86484 68.37 (66.64-70.14) 
Men Missing BMI ≤5 years 1207 52318 23.07 (21.79-24.41) 
Non-missing BMI ≤5 years 5614 368581 15.23 (14.84-15.64) 
Missing BMI >5 years 851 23819 35.73 (33.37-38.21) 
Non-missing BMI >5 years 5054 165382 30.56 (29.72-31.41) 
Women Missing BMI ≤5 years 1003 38984 25.73 (24.16-27.37) 
Non-missing BMI ≤5 years 3343 245786 13.60 (13.14-14.07) 
Missing BMI >5 years 781 17936 43.54 (40.54-46.71) 
Non-missing BMI >5 years 3535 112923 31.30 (30.28-32.35) 
Non-
smokers Missing BMI ≤5 years 255 29212 8.73 ( 7.69- 9.87) 
Non-missing BMI ≤5 years 1600 299990 5.33 ( 5.08- 5.60) 
Missing BMI >5 years 304 17202 17.67 (15.74-19.77) 
Non-missing BMI >5 years 1656 143163 11.57 (11.02-12.14) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S20 - Crude mortality rates for CVD mortality among patients with 
missing/non-missing BMI 
Group 
Missing/non-
missing BMI 
Mortality by 
time period Events 
Person 
years 
Mortality rate/1000 
person years 
Overall Missing BMI ≤5 years 1028 91302 11.26 (10.58-11.97) 
BMI measured ≤5 years 3638 614367  5.92 ( 5.73- 6.12) 
Missing BMI >5 years 695 41755 16.64 (15.43-17.93) 
BMI measured >5 years 3580 278305 12.86 (12.45-13.29) 
<65 Missing BMI ≤5 years 200 56618 3.53 (3.06-4.06) 
BMI measured ≤5 years 891 409580 2.18 (2.03-2.32) 
Missing BMI >5 years 161 27609 5.83 (4.97-6.81) 
BMI measured >5 years 928 191821 4.84 (4.53-5.16) 
>65 Missing BMI ≤5 years 828 34684 23.87 (22.27-25.56) 
BMI measured ≤5 years 2747 204787 13.41 (12.92-13.93) 
Missing BMI >5 years 534 14146 37.75 (34.61-41.09) 
BMI measured >5 years 2652 86484 30.66 (29.51-31.85) 
Men Missing BMI ≤5 years 555 52318 10.61 ( 9.74-11.53) 
BMI measured ≤5 years 2316 368581  6.28 ( 6.03- 6.54) 
Missing BMI >5 years 370 23819 15.53 (13.99-17.20) 
BMI measured >5 years 2094 165382 12.66 (12.13-13.22) 
Women Missing BMI ≤5 years 473 38984 12.13 (11.06-13.28) 
BMI measured ≤5 years 1322 245786  5.38 ( 5.09- 5.68) 
Missing BMI >5 years 325 17936 18.12 (16.20-20.20) 
BMI measured >5 years 1486 112923 13.16 (12.50-13.85) 
Non-
smokers Missing BMI ≤5 years 96 29212 3.29 (2.66-4.01) 
BMI measured ≤5 years 106 17202 6.16 (5.05-7.45) 
Missing BMI >5 years 491 299990 1.64 (1.50-1.79) 
BMI measured >5 years 574 143163 4.01 (3.69-4.35) 
Legends: Events and person years are presented as numbers. Incidence rate is presented as mean 
(CI 95%) 
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Supplementary table S21 - Fully adjusted hazard ratio (HR) for death from any cause by BMI 
group and time, among patients only with missing BMI. Patients with non-missing BMI used as 
reference. 
Group Mortality by time period HR estimate Lower CI 95% Upper CI 95% 
Overall ≤5 years 1.41 1.32 1.50 
>5 years 1.14 1.06 1.22 
<65 years ≤5 years 1.32 1.20 1.44 
>5 years 1.16 1.05 1.29 
≥65 years ≤5 years 1.44 1.34 1.55 
>5 years 1.14 1.05 1.23 
Men ≤5 years 1.30 1.18 1.42 
>5 years 1.06 0.95 1.17 
Women ≤5 years 1.48 1.38 1.59 
>5 years 1.17 1.08 1.27 
Non-smokers ≤5 years 1.45 1.27 1.66 
>5 years 1.39 1.23 1.57 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
 
Supplementary table S22 – Fully adjusted hazard ratio (HR) for death from CVD causes by BMI 
group and time, among patients only with missing BMI. Patients with non-missing BMI used as 
reference. 
Group Mortality by time period HR estimate Lower CI 95% Upper CI 95% 
Overall ≤5 years 1.47 1.37 1.58 
>5 years 1.07 0.98 1.16 
<65 years ≤5 years 1.31 1.03 1.65 
>5 years 1.10   0.86 1.40 
≥65 years ≤5 years 1.49 1.37 1.61 
>5 years 1.04 0.94 1.14 
Men ≤5 years 1.39 1.27 1.53 
>5 years 1.04 0.93 1.16 
Women ≤5 years 1.61 1.44 1.80 
>5 years 1.10 0.97 1.25 
Non-smokers ≤5 years 1.64 1.31  2.07 
>5 years 1.41 1.14 1.74 
Legends: The analysis based on cox regression was adjusted for age group, year of inclusion, sex, 
the interaction between duration of diabetes and age, income, education, marital status, immigrant 
status, coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and 
chronic kidney disease. Variables that were non-proportional were adjusted for by stratification into 
the overall hazard ratio. 
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Legends: White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis 
based on cox regression was adjusted for age group, year of inclusion, the interaction between 
duration of diabetes and age, income, education, marital status, immigrant status, coronary heart 
disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and chronic kidney disease. 
Variables that were non-proportional were adjusted for by stratification into the overall hazard ratio. 
Panel A, All-cause mortality, HR by BMI group and time (men only). Panel B, CVD mortality, HR by 
BMI group and time (men only).  
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Legends: White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis 
based on cox regression was adjusted for age group, year of inclusion, the interaction between 
duration of diabetes and age, income, education, marital status, immigrant status, coronary heart 
disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and chronic kidney disease. 
Variables that were non-proportional were adjusted for by stratification into the overall hazard ratio. 
Panel A, All-cause mortality, HR by BMI group and time (women only). Panel B, CVD mortality, HR by 
BMI group and time (women only). 
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Legends: White squares = mortality ≤5 years; black diamonds = mortality >5 years. The analysis 
based on cox regression was adjusted for age group, year of inclusion, sex, the interaction between 
duration of diabetes and age, income, education, marital status, immigrant status, coronary heart 
disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and chronic kidney disease. 
Variables that were non-proportional were adjusted for by stratification into the overall hazard ratio. 
Panel A (All-cause mortality, HR by BMI group and time (age <65 years, non-smoking patients). Panel 
B CVD mortality, HR by BMI group and time (age <65 years, non-smoking patients).  
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